Untreated HIV infection results in not only in the progressive loss of T cell immune function, but also in chronic polyclonal B cell activation. The risk for developing B cell non-Hodgkin's lymphoma also is greatly elevated in HIV+ persons. Virtually all AIDS-related lymphomas (ARL) are of B cell origin. HIV infection-associated B cell hyperactivation is believed to play a central role in the genesis of ARL, as B cell activation involves two molecular processes that can create the seminal molecular lesions seen in ARL: 1) immunoglobulin heavy chain gene (IgH) class switch recombination (CSR), a process that involves double-strand DNA breaks and recombination, and 2) somatic hypermutation (SHM), DNA hypermutation of the variable region of antibody genes. Errors in IgH CSR and SHM can lead directly to oncogene mutations and/or translocations that result in ARL. IgH CSR and SHM are both mediated by activation-induced cytidine deaminase (AICDA), a member of the APOBEC family. In our prior work, we saw that PBMC B cell AICDA expression was elevated for several years preceding the diagnosis of ARL, as were serum levels of B cell stimulatory cytokines. We also found that HIV virions carrying CD40 ligand (CD40L), a T cell-produced B cell stimulatory molecule, can drive B cell activation and AICDA expression. Given that HIV can potently induce B cell activation via host cell- encoded stimulatory molecules incorporated into virions, and that B cell activation can contribute to the development of ARL, it is important to better define the role of such virion-associated stimulatory molecules in driving B cell activation With this in mind, the specific aims of this study are to: 1) define the ability of CD40L+ HIV to promote oncogenic events in B cells, 2) define the expression of CD40L on HIV virions in vivo, throughout the course of HIV disease, and 3) determine if the development of ARL is associated with elevated expression of CD40L or other B cell-stimulatory molecules on HIV virions from plasma, as well as with a gene expression pattern in circulating T cells that is characteristic of TFH/TH17 cells, elevated serum levels of B cell- stimulatory cytokines, and/or, elevated plasma levels of EBV and/or KSHV DNA. By better defining the association of CD40L+ HIV and ARL we hope to elucidate the pathogenesis of these cancers, providing information that will inform future work on risk assessment and early detection, and on the development of therapeutics.

Public Health Relevance

The risk of developing B cell non-Hodgkin's lymphoma (NHL) is greatly increased in those persons who have HIV infection. AIDS-related NHL (ARL) is now the most common AIDS-related malignancy in developed countries with access to effective multi-agent anti-retroviral treatment (HAART), accounting for 23-30% of AIDS-related causes of death. By better defining how HIV promotes the development of ARL, we will identify factors that are important in the etiology and pathogenesis of these cancers, which may be useful pre-cancer biomarkers for early detection and the development of prophylactic strategies for these common HIV infection associated cancers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
AIDS Immunology and Pathogenesis Study Section (AIP)
Program Officer
Read-Connole, Elizabeth Lee
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Obstetrics & Gynecology
Schools of Medicine
Los Angeles
United States
Zip Code
Epeldegui, Marta; Magpantay, Larry; Guo, Yu et al. (2018) A prospective study of serum microbial translocation biomarkers and risk of AIDS-related non-Hodgkin lymphoma. AIDS 32:945-954
Halec, Gordana; Waterboer, Tim; Brenner, Nicole et al. (2018) Serological Assessment of 18 Pathogens and Risk for AIDS-associated Non-Hodgkin Lymphoma. J Acquir Immune Defic Syndr :
Almagro, Juan C; Daniels-Wells, Tracy R; Perez-Tapia, Sonia Mayra et al. (2017) Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy. Front Immunol 8:1751
Peckham-Gregory, Erin C; Thapa, Dharma R; Martinson, Jeremy et al. (2016) MicroRNA-related polymorphisms and non-Hodgkin lymphoma susceptibility in the Multicenter AIDS Cohort Study. Cancer Epidemiol 45:47-57
Epeldegui, Marta; Lee, Jeannette Y; Martínez, Anna C et al. (2016) Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial). Clin Cancer Res 22:328-36
Daniels-Wells, Tracy R; Penichet, Manuel L (2016) Transferrin receptor 1: a target for antibody-mediated cancer therapy. Immunotherapy 8:991-4
Epeldegui, Marta; Martínez-Maza, Otoniel (2015) Immune Activation: Contribution to AIDS-Associated Non-Hodgkin Lymphoma. For Immunopathol Dis Therap 6:79-90
Daniels-Wells, Tracy R; Widney, Daniel P; Leoh, Lai Sum et al. (2015) Efficacy of an Anti-transferrin Receptor 1 Antibody Against AIDS-related Non-Hodgkin Lymphoma: A Brief Communication. J Immunother 38:307-10
Leoh, Lai Sum; Daniels-Wells, Tracy R; Martínez-Maza, Otoniel et al. (2015) Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1. Mol Immunol 67:407-15
Thapa, Dharma R; Hussain, Shehnaz K; Tran, Wen-Ching et al. (2014) Serum microRNAs in HIV-infected individuals as pre-diagnosis biomarkers for AIDS-NHL. J Acquir Immune Defic Syndr 66:229-37

Showing the most recent 10 out of 15 publications